BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ampuero J, Aller R, Gallego-Durán R, Banales JM, Crespo J, García-Monzón C, Pareja MJ, Vilar-Gómez E, Caballería J, Escudero-García D, Gomez-Camarero J, Calleja JL, Latorre M, Albillos A, Salmeron J, Aspichueta P, Lo Iacono O, Francés R, Benlloch S, Fernández-Rodríguez C, García-Samaniego J, Estévez P, Andrade RJ, Turnes J, Romero-Gómez M; HEPAmet Registry. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther 2018;48:1260-70. [PMID: 30353552 DOI: 10.1111/apt.15015] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Yılmaz Y, Kanı HT, Demirtaş CÖ, Kaya E, Sapmaz AF, Qutranji L, Alkayyali T, Batun KD, Batman M, Toy B, Çiftaslan A. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience. Turk J Gastroenterol 2019;30:892-8. [PMID: 31258138 DOI: 10.5152/tjg.2019.19072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
2 Frey S, Patouraux S, Debs T, Gugenheim J, Anty R, Iannelli A. Prevalence of NASH/NAFLD in people with obesity who are currently classified as metabolically healthy. Surg Obes Relat Dis 2020;16:2050-7. [PMID: 32788075 DOI: 10.1016/j.soard.2020.07.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Ampuero J, Aller R, Gallego-Durán R, Crespo J, Abad J, González-Rodríguez Á, Gómez-Camarero J, Caballería J, Lo Iacono O, Ibañez L, García-Samaniego J, Martín-Mateos R, Francés R, Fernández-Rodríguez C, Diago M, Soriano G, Andrade RJ, Latorre R, Jorquera F, Morillas RM, Escudero D, Estévez P, Hernández-Guerra M, Augustín S, Pareja-Megia MJ, Banales JM, Aspichueta P, Benlloch S, Rosales JM, Salmerón J, Turnes J, Romero-Gómez M; HEPAmet Registry. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. Liver Int 2021;41:2076-86. [PMID: 33896100 DOI: 10.1111/liv.14898] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Ampuero J, Romero-Gomez M. Stratification of patients in NASH clinical trials: A pitfall for trial success. JHEP Rep 2020;2:100148. [PMID: 32954243 DOI: 10.1016/j.jhepr.2020.100148] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
5 Llop E, Iruzubieta P, Perelló C, Fernández Carrillo C, Cabezas J, Escudero MD, González M, Hernández Conde M, Puchades L, Arias-Loste MT, Serra MÁ, Crespo J, Calleja JL. High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort. United European Gastroenterol J 2021. [PMID: 34077628 DOI: 10.1002/ueg2.12109] [Reference Citation Analysis]
6 Hernández-Conde M, Llop E, Fernández Carrillo C, Tormo B, Abad J, Rodriguez L, Perelló C, López Gomez M, Martínez-Porras JL, Fernández Puga N, Trapero-Marugan M, Fraga E, Ferre Aracil C, Calleja Panero JL. Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease. World J Gastroenterol 2020; 26(42): 6658-6668 [PMID: 33268953 DOI: 10.3748/wjg.v26.i42.6658] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Liu CH, Ampuero J, Pavlides M, Wong VW, Fan JG, Bai L, Li H, Wu DB, Zhou LY, Du LY, Yang TK, Jiang W, Shi Y, Gil-Gómez A, Zhang WT, Liang JX, Romero-Gómez M, Tang H. Simple non-invasive scoring systems and histological scores in predicting mortality in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36:1754-68. [PMID: 33569851 DOI: 10.1111/jgh.15431] [Reference Citation Analysis]
8 Eslam M, Fan J, Mendez-sanchez N. Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health. The Lancet Gastroenterology & Hepatology 2020;5:713-5. [DOI: 10.1016/s2468-1253(20)30090-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 15.0] [Reference Citation Analysis]
9 Ampuero J, Pais R, Aller R, Gallego-Durán R, Crespo J, García-Monzón C, Boursier J, Vilar E, Petta S, Zheng MH, Escudero D, Calleja JL, Aspichueta P, Diago M, Rosales JM, Caballería J, Gómez-Camarero J, Lo Iacono O, Benlloch S, Albillos A, Turnes J, Banales JM, Ratziu V, Romero-Gómez M; HEPAmet Registry. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. Clin Gastroenterol Hepatol 2020;18:216-225.e5. [PMID: 31195161 DOI: 10.1016/j.cgh.2019.05.051] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 18.0] [Reference Citation Analysis]
10 Khayyat YM. Lean non-alcoholic fatty liver disease and associated metabolic disturbance: A Saudi Arabian cross-sectional study. Physiol Rep 2021;9:e14949. [PMID: 34278728 DOI: 10.14814/phy2.14949] [Reference Citation Analysis]
11 Lee HW, Wong GL, Kwok R, Choi KC, Chan CK, Shu SS, Leung JK, Chim AM, Luk AO, Ma RC, Chan HL, Chan JC, Kong AP, Wong VW. Serial transient elastography examinations to monitor patients with type 2 diabetes: A prospective cohort study. Hepatology. 2020;. [PMID: 31991487 DOI: 10.1002/hep.31142] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
12 Goday A, Julià H, de Vargas-Machuca A, Pedro-Botet J, Benavente S, Ramon JM, Pera M, Casajoana A, Villatoro M, Fontané L, Bisbe M, Climent E, Castañer O, Flores Le Roux JA, Benaiges D. Bariatric surgery improves metabolic and nonalcoholic fatty liver disease markers in metabolically healthy patients with morbid obesity at 5 years. Surg Obes Relat Dis 2021:S1550-7289(21)00384-1. [PMID: 34509375 DOI: 10.1016/j.soard.2021.07.021] [Reference Citation Analysis]
13 Gómez-Hurtado I, Gallego-Durán R, Zapater P, Ampuero J, Aller R, Crespo J, Arias-Loste M, García-Monzón C, Bellot P, González-Rodríguez Á, Juanola O, Romero-Gómez M, Francés R. Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients. Liver Int 2020;40:2182-93. [PMID: 32559006 DOI: 10.1111/liv.14571] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
14 Lonardo A, Mantovani A, Lugari S, Targher G. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. Ann Hepatol. 2020;19:359-366. [PMID: 32349939 DOI: 10.1016/j.aohep.2020.03.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 22.0] [Reference Citation Analysis]
15 Buzzetti E, Hall A, Ekstedt M, Manuguerra R, Guerrero Misas M, Covelli C, Leandro G, Luong T, Kechagias S, Manesis EK, Pinzani M, Dhillon AP, Tsochatzis EA. Collagen proportionate area is an independent predictor of long-term outcome in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2019;49:1214-22. [PMID: 30882933 DOI: 10.1111/apt.15219] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 12.0] [Reference Citation Analysis]
16 Xue J, Zhao Y, Wang Z, Ren N, Zhou C, Qin S. Rotating night shift work is associated with an increased risk of gastroesophageal reflux disease (GERD) symptoms among workers in China: A cross-sectional study. Int J Clin Pract 2021;75:e13848. [PMID: 33220144 DOI: 10.1111/ijcp.13848] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-gomez M, Zelber-sagi S, Wai-sun Wong V, Dufour J, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-järvinen H, Fan J, Grønbæk H, Yilmaz Y, Cortez-pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng M, Fouad Y, Chan W, Mendez-sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology 2020;73:202-9. [DOI: 10.1016/j.jhep.2020.03.039] [Cited by in Crossref: 390] [Cited by in F6Publishing: 420] [Article Influence: 390.0] [Reference Citation Analysis]
18 Solfrizzi V, Scafato E, Custodero C, Loparco F, Ciavarella A, Panza F, Seripa D, Imbimbo BP, Lozupone M, Napoli N, Piazzolla G, Galluzzo L, Gandin C, Baldereschi M, Di Carlo A, Inzitari D, Pilotto A, Sabbà C; Italian Longitudinal Study on Aging Working Group. Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging. Alzheimers Dement (N Y) 2020;6:e12065. [PMID: 32864415 DOI: 10.1002/trc2.12065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Heda R, Yazawa M, Shi M, Bhaskaran M, Aloor FZ, Thuluvath PJ, Satapathy SK. Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect. World J Gastroenterol 2021; 27(17): 1864-1882 [PMID: 34007127 DOI: 10.3748/wjg.v27.i17.1864] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Konerman MA, Walden P, Joseph M, Jackson EA, Lok AS, Rubenfire M. Impact of a structured lifestyle programme on patients with metabolic syndrome complicated by non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2019;49:296-307. [PMID: 30561027 DOI: 10.1111/apt.15063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
21 Cheng YM, Kao JH, Wang CC. The metabolic profiles and body composition of lean metabolic associated fatty liver disease. Hepatol Int 2021;15:405-12. [PMID: 33539004 DOI: 10.1007/s12072-021-10147-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Negro F. Natural history of NASH and HCC. Liver Int 2020;40:72-6. [DOI: 10.1111/liv.14362] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 26.0] [Reference Citation Analysis]
23 Flisiak-Jackiewicz M, Bobrus-Chociej A, Wasilewska N, Lebensztejn DM. From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-New Terminology in Pediatric Patients as a Step in Good Scientific Direction? J Clin Med 2021;10:924. [PMID: 33804296 DOI: 10.3390/jcm10050924] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Song DS, Chang UI, Kang SG, Song SW, Yang JM. Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease. Gut Liver 2019;13:658-68. [PMID: 30970434 DOI: 10.5009/gnl18439] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
25 Abeles RD, Mullish BH, Forlano R, Kimhofer T, Adler M, Tzallas A, Giannakeas N, Yee M, Mayet J, Goldin RD, Thursz MR, Manousou P. Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease; the importance of an elevated mean platelet volume. Aliment Pharmacol Ther. 2019;49:1077-1085. [PMID: 30836450 DOI: 10.1111/apt.15192] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
26 Zhang X, Li R, Chen Y, Dai Y, Chen L, Qin L, Cheng X, Lu Y. The Role of Thyroid Hormones and Autoantibodies in Metabolic Dysfunction Associated Fatty Liver Disease: TgAb May Be a Potential Protective Factor. Front Endocrinol (Lausanne) 2020;11:598836. [PMID: 33363517 DOI: 10.3389/fendo.2020.598836] [Reference Citation Analysis]
27 Zou ZY, Wong VW, Fan JG. Epidemiology of nonalcoholic fatty liver disease in non‐obese populations: Meta‐analytic assessment of its prevalence, genetic, metabolic, and histological profiles. J Dig Dis 2020;21:372-84. [DOI: 10.1111/1751-2980.12871] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
28 Ampuero J, Aller R, Gallego-durán R, Crespo J, Calleja JL, García-monzón C, Gómez-camarero J, Caballería J, Lo Iacono O, Ibañez L, García-samaniego J, Albillos A, Francés R, Fernández-rodríguez C, Diago M, Soriano G, Andrade RJ, Latorre R, Jorquera F, Morillas RM, Escudero D, Estévez P, Guerra MH, Augustín S, Banales JM, Aspichueta P, Benlloch S, Rosales JM, Salmerón J, Turnes J, Romero Gómez M. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. Journal of Hepatology 2020;73:17-25. [DOI: 10.1016/j.jhep.2020.02.028] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
29 Tutunchi H, Naeini F, Ebrahimi-Mameghani M, Najafipour F, Mobasseri M, Ostadrahimi A. Metabolically healthy and unhealthy obesity and the progression of liver fibrosis: A cross-sectional study. Clin Res Hepatol Gastroenterol 2021;45:101754. [PMID: 34303827 DOI: 10.1016/j.clinre.2021.101754] [Reference Citation Analysis]
30 Ampuero J, Gallego-Durán R, Romero-Gómez M. Reply to: "The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD". J Hepatol 2021;74:971-2. [PMID: 33359898 DOI: 10.1016/j.jhep.2020.12.020] [Reference Citation Analysis]
31 Guo Q, Zhou S, Feng X, Yang J, Qiao J, Zhao Y, Shi D, Zhou Y. The sensibility of the new blood lipid indicator--atherogenic index of plasma (AIP) in menopausal women with coronary artery disease. Lipids Health Dis 2020;19:27. [PMID: 32093690 DOI: 10.1186/s12944-020-01208-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
32 Åberg F, Färkkilä M, Männistö V. Interaction Between Alcohol Use and Metabolic Risk Factors for Liver Disease: A Critical Review of Epidemiological Studies. Alcohol Clin Exp Res 2020;44:384-403. [DOI: 10.1111/acer.14271] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
33 Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, Yang H, Liu C, Kam LY, Tan XXE, Chien N, Trinh S, Henry L, Stave CD, Hosaka T, Cheung RC, Nguyen MH. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739-752. [PMID: 32413340 DOI: 10.1016/s2468-1253(20)30077-7] [Cited by in Crossref: 85] [Cited by in F6Publishing: 42] [Article Influence: 85.0] [Reference Citation Analysis]
34 Li H, Guo M, An Z, Meng J, Jiang J, Song J, Wu W. Prevalence and Risk Factors of Metabolic Associated Fatty Liver Disease in Xinxiang, China. Int J Environ Res Public Health 2020;17:E1818. [PMID: 32168920 DOI: 10.3390/ijerph17061818] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
35 Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919. [PMID: 33006093 DOI: 10.1007/s12072-020-10094-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 68] [Article Influence: 61.0] [Reference Citation Analysis]